SCHEMBL355638

SCHEMBL355638

COc1ccc(OC)c2c1CC/C2=N\O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
GAA P10253 2/20 0.55
GLA P06280 1/20 0.55
EGFR P00533 1/20 0.44
ACHE P22303 1/20 0.39
ADRA1A P35348 3/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 4/20 0.35
MAPK1 P28482 2/20 0.35
ALOX15 P16050 1/20 0.35
HIF1A Q16665 1/20 0.34
EPAS1 Q99814 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355639 1.00 KDM4E (0.55) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL5461808 0.89 ALDH1A1 (0.47) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL5461811 0.89 ALDH1A1 (0.47) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL3411143 0.88 KDM4E (0.42) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL4103085 0.88 KDM4E (0.42) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL659339 0.75 LMNA (0.45) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL166263 0.75 BRAF (0.51) KDM4EHPGDACHEHSD17B10MAPT
SCHEMBL659340 0.75 LMNA (0.45) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL166262 0.75 BRAF (0.51) KDM4EHPGDACHEHSD17B10MAPT
SCHEMBL8690757 0.74 ALDH1A1 (0.43) KDM4EALDH1A1HPGDGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-8044100-B2 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH INC. (CA) 2011-10-25 US disclosed
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223855-A1 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity APP, IAPP, BACE1 KDM4E 4831/4885ALDH1A1 2230/4885HPGD 1716/4885
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 KDM4E 4713/4885ALDH1A1 2989/4885HPGD 1438/4885
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 KDM4E 4793/4885ALDH1A1 3131/4885HPGD 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.